PBH is a form of reactive hypoglycemia that usually presents 6 months to 4 years post-surgery and is caused by increased postprandial circulating glucose and a resulting uncontrolled spike in insulin, typically occurring 1-2 hours after a meal. Symptoms can include those associated with neuroglycopenia such as weakness, drowsiness, dizziness, confusion, seizure and loss of consciousness that can dangerously impair normal day-to-day activities and can sometimes be life-threatening. 

Mizagliflozin, a small molecule therapeutic targeted at PBH, a metabolic disease with a growing high unmet medical need. Mizagliflozin is a minimally absorbed inhibitor of SGLT1 being developed by Vogenx for the treatment of PBH.